Issn Print: 0923-7534
Publication Date: 2017/12/01
Response to ‘Survival advantage for etoposide/cisplatin over paclitaxel/carboplatin concurrent chemoradiation in patients with inoperable stage III NSCLC: a subgroup analysis for ECOG 2 patients would be of great interest’
N Bi; J Liang; L Wang
|Checking for direct PDF access through Ovid|
Abstract unavailable for this article.